News
NHS approves new treatment for advanced womb cancer
The combination has been shown to stimulate the body’s immune system and kill off cancer cell growth

Hundreds of women with advanced womb cancer in England are to be offered a new “lifeline” option, as the NHS rolls out a new combination therapy that could halt the progression of the disease.
The NHS has agreed landmark commercial deals for two drugs from different manufacturers, which will be used in combination to treat advanced endometrial cancer in between 500 and 750 women each year.
Clinical trials have shown that pembrolizumab and lenvatinib used together can double the time taken for cancer to progress compared with the existing chemotherapy treatment, from just over three and half months to more than seven months.
In the trial, overall survival was also significantly longer for patients taking the combination therapy compared to existing chemotherapy treatments, with those taking pembrolizumab and lenvatinib living on average almost 19 months compared just under 12 months on existing chemotherapy.
Set for approval today by the National Institute for Health and Care Excellence (NICE), the combination has been shown to stimulate the body’s immune system and kill off cancer cell growth.
As part of the combination treatment, pembrolizumab is delivered intravenously every three or six weeks while lenvatinib is two pills taken once a day.
Currently, patients undergo chemotherapy treatment every three weeks, but unlike with chemotherapy, there is a far less significant risk of hair loss as a side effect of the new combination treatment.
Around 9,400 women are diagnosed with cancer in the womb every year, making it the fourth most common cancer in UK women.
While the treatment was initially rejected in draft guidance by NICE on the grounds of cost-effectiveness, the NHS has been able to use its commercial capabilities to negotiate a deal with the manufacturers, allowing the treatment to be made available to patients.
“It is fantastic news that this innovative combination therapy can now offer a new lifeline to hundreds of women living with advanced endometrial cancer, giving hope of precious extra time to live with a better quality of life,” said NHS national cancer director Professor Peter Johnson.
“Now in its 75th year, the NHS is leading the world in making the latest treatments available through its unique commercial capabilities and commitment to innovation on behalf of patients and their families across the country.”
Grace Teeling, a 33-year-old from Bristol who was diagnosed with advanced stage three womb cancer in 2019, said: “I have been incredibly fortunate to receive treatment for the past two years and I had a really good response, which means there is currently no evidence of cancer on my recent scans,” she said.
“It has enabled me to thrive despite having an advanced and incurable cancer diagnosis.
“I am able to work, travel, socialise and exercise, including paddleboarding, which I may not have been able to do on chemotherapy. I am delighted others will now be able to access this treatment as I don’t think I would be alive today if I hadn’t.”
Professor Emma Crosbie, chair of trustees of Peaches Womb Cancer Trust, said: “This innovative new treatment regimen will benefit patients with advanced or recurrent endometrial cancer, who currently have very few effective anti-cancer treatments available to them.
“Every year, many people are facing a diagnosis of advanced or recurrent womb cancer, and the frightening reality of very few treatment options that can improve their survival and quality of life.
“Those affected by womb cancer deserve more treatment options, but we hope that this is just the first step towards wider availability of more effective treatment options for those affected by this devastating cancer.”
David Long, head of oncology at MSD UK, which manufactures pembrolzimab, said: “Endometrial cancer is one of the few cancers with rising incidence and mortality, and historically there has been limited treatment options for people with advanced stages of the disease.
“We are therefore very pleased that a new treatment option has been made available to patients which will help address this unmet need.
“We are proud to have worked alongside Eisai, NICE and NHS England to ensure patients can access this treatment.”
The combination treatment will be funded by the NHS and will be offered to all eligible women who have previously received treatment for advanced or recurrent endometrial cancer.
Entrepreneur
Fertility startup American Baby Company secures US$4m

A fertility startup has raised US$4m and will open its first lower-cost IVF clinic in West Palm Beach later this year.
It will offer a full IVF cycle, including medications, for US$8,995.
Around 12 per cent of American couples struggle with infertility, according to the company, but only 14 per cent of them receive IVF because of the cost.
A single IVF cycle costs an average of US$23,500, it said, with the cost nearly doubling if further cycles are needed.
Co-founder and chief executive Van Spina said: “We’re building ABC around a straightforward premise: IVF has become unnecessarily expensive, and many patients are priced out before they ever have a real chance to start a family.”
“This is personal for me. My fiancée and I went through IVF ourselves, including multiple failed cycles,” Spina continued, citing Jamie Rapp.
“That experience pushed me to build the kind of fertility company we wished had existed when we began treatment.”
The US$4m seed round was led by Wormhole Capital and Tower Research Ventures.
In a blog post, New York-based Tower Research described ABC as a new model for fertility care, praising its “evidence-based protocols, AI-assisted intake, and modern lab workflows.”
“When we met the team at The American Baby Company (ABC), we saw an opportunity to rethink how fertility care is delivered in the US from the ground up,” the post said.
Co-founder and chief medical officer Dr Paul Magarelli is a board-certified reproductive endocrinologist and one of the most prominent voices in the US on expanding access to fertility care, according to Tower.
Reproductive endocrinology is a branch of medicine concerned with hormones and fertility.
Magarelli developed the Clinical Fertility Physician certification programme, which trains generalist clinicians to deliver routine fertility procedures under specialist oversight.
Spina spent his early career as a technology investor at Warburg Pincus before founding an institutionally backed data business in private credit.
“We’re on a mission to become the place Americans go to start their families,” Spina said.
“Our 10-year goal is to help make 250,000 babies per year.”
Wellness
Yoga and omega-3 as effective as therapy for depression in pregnancy, research finds

Yoga and omega-3 supplements may be as effective as talking therapies for pregnancy depression, a major review suggests.
Globally, nearly one in three pregnant women experience depression, but most receive no treatment.
When support is available, women are often directed towards talking therapies such as cognitive behavioural therapy, or CBT, and mindfulness.
CBT is a structured talking therapy that helps people identify and change patterns of thought and behaviour affecting their mental health.
The review examined 115 clinical trials involving more than 12,000 participants across 30 countries.
It found that yoga, massage, omega-3 supplements and bright light therapy were broadly as effective as talking therapies at reducing depression symptoms during pregnancy.
Bright light therapy involves controlled exposure to bright light and is sometimes used to treat mood conditions.
The findings point to the importance of social support and increased connection, as all these approaches offer some element of contact or guided support.
Led by King’s College London, the research brought together trial evidence across every type and format of treatment for antenatal depression under a common framework.
Antenatal depression is depression that occurs during pregnancy.
The study was conducted as part of HappyMums, a European consortium led by the University of Milan that aims to improve mental health support during pregnancy and after birth.
Carmine Pariante, professor of biological psychiatry, said: “This is the most comprehensive analysis of treatments for depression in pregnancy ever conducted, and the findings should prompt a rethink of how we support women during this critical period.
“The evidence is clear that there is no single best approach. What matters is that women have access to a range of options, and that clinicians feel equipped to offer them.”
The researchers said yoga and omega-3 supplements could be legitimate treatment options, rather than stopgaps, for women on waiting lists or those who struggle to access mental health support.
However, the studies differed considerably in design, sample size and how results were measured, so the findings should be interpreted with care.
The team said non-psychological approaches could help women cope with long waits for care without ruling out other treatments alongside them.
Digital and online interventions, including apps and telephone-based support, were also found to be as effective as face-to-face treatment.
Researchers said this could affect how antenatal depression is managed, particularly for women who cannot travel or face long waits for in-person care.
The team found no randomised controlled trials of pharmaceutical treatments for antenatal depression, despite antidepressants being widely prescribed for depression outside pregnancy.
A randomised controlled trial is a study in which participants are randomly assigned to different treatment groups, allowing researchers to compare outcomes more fairly.
Evidence for drug treatment during pregnancy therefore relies on indirect research rather than trials carried out during pregnancy, reflecting long-standing caution around testing medicines in pregnant populations.
NICE guidelines recommend antidepressants for moderate to severe depression in pregnancy, while evidence from outside formal pregnancy trials suggests they can be safe and effective.
However, the researchers said trials are still needed, particularly for women who cannot access or engage with other forms of support.
Riddhi Laijawala, trial manager and PhD student, said: “Depression in pregnancy is common, but it is not inevitable, and it is treatable. What this review shows is that the options available to women are broader than many people realise.
“A yoga class, music therapy, or an online programme may not sound like clinical treatment, but the evidence suggests they can make a real difference, and for many women they may be easier (and quicker) to access than a course of therapy.”
Depression during pregnancy affects an estimated 28.5 per cent of pregnant people worldwide, but only around one in five receives appropriate and timely treatment.
The team said closing this treatment gap should be a priority for health systems because the condition can affect both parent and child.
The HappyMums project is supported by the European Union’s Horizon Europe research and innovation programme.
Hormonal health
Type 2 diabetes rising among young women, experts warn

Type 2 diabetes is rising among women in their 20s in England, with experts warning of a worrying increase since the Covid pandemic.
The rise has largely occurred since the pandemic and is closely linked to increasing obesity levels, according to an analysis of NHS data from 2011 to 2024.
The condition is serious and can lead to severe complications, including heart attacks and strokes.
Diabetes UK said it tends to be more aggressive when it develops at a younger age, raising the risk of serious complications and shorter lives.
The charity said early diagnosis is vital for people at risk to help prevent long-term organ damage.
The condition can sometimes be put into remission through healthy eating and maintaining a healthy weight, without relying on glucose-lowering medicines.
Researchers said newer obesity treatments, including GLP-1 injections and pills, may also help alongside healthy eating advice.
About 90 per cent of the six million people living with diabetes in the UK have type 2 rather than type 1, or insulin-dependent, diabetes.
The risk increases with age, and older adults still account for the largest proportion of new diagnoses.
However, NHS England estimates suggest that 12,000 people under 30 are now living with the condition, with women making up more of the younger cases.
Common symptoms include feeling very tired, urinating more often than usual and feeling thirsty all the time.
Researchers at Imperial College London analysed NHS data from the English National Diabetes Audit to examine trends over time.
The figures showed that cases are falling slightly among older adults, who still account for the largest share of new diagnoses.
However, diagnoses are increasing rapidly among people under 40, with some of the sharpest rises among women aged 20 to 29.
Body mass index at diagnosis has also been rising more quickly among younger adults than in older age groups, pointing to obesity as a likely factor.
Body mass index, or BMI, is a measure of obesity based on a person’s height and weight.
Separate NHS data for England shows obesity rates have worsened since the pandemic, with nearly one in three people now affected.
The largest increases over time have been among younger adults.
Between 2019 and 2025, new obesity cases rose by 16 per cent among people aged 20 to 29 and by almost 20 per cent among those aged 30 to 39.
Rates fell among adults aged 60 to 79 over the same period.
Lead researcher Dr Shivani Misra said: “We think that the earlier onset of severe obesity in young people is increasing their type 2 diabetes risk in early life and pulling down their age at diagnosis.
“This is really worrying given the poor health outcomes from early-onset type 2 diabetes.”
Misra said much of the discussion about rising rates among younger people had focused on ethnic minority groups, which have traditionally been considered at higher risk.
However, the new data suggests the trend extends well beyond those communities.
She added: “We now see that incidence is also increasing in white populations too, showing that this public health challenge is broadening across the generations.”
Diabetes UK said better follow-up care is also needed for mums-to-be diagnosed with gestational diabetes during pregnancy because it raises the risk of developing type 2 diabetes after childbirth.
Some studies have suggested that the risk of developing the condition may also increase after being ill with Covid, although the evidence remains inconclusive.
Menopause2 weeks agoNew menopause drug approved for use by NHS in Scotland
Wellness1 week agoStardust period tracker shares health data, study reveals
News6 days agoZero Candida market set to reach over US$2 billion by 2030 – report
News2 weeks agoWomen’s health draws record $1.55bn in equity as capital spreads beyond the mega-rounds
Insight2 weeks agoSoftening ovaries could extend fertility as women age, study suggests
Entrepreneur2 weeks agoOnto Health acquires diagnostics software company Levy Health
News1 week agoCongress urged to invest over $20bn to close women’s health gap
Mental health1 week agoNearly 60% of young women get health advice from influencers, research finds











